Journal: Frontiers in Oncology

Article Title: Combined Association of Tumoral PD-L1 Expression and Pretreatment Presence of Epstein-Barr Virus DNA With Risk Stratification and Prognosis of Patients With Nasopharyngeal Carcinoma

doi: 10.3389/fonc.2021.791411

Figure Lengend Snippet: Association between PD-L1 expression and clinicopathological features of patients with NPC.

Article Snippet: The sections were stained overnight at 4°C with anti-PD-L1 primary antibody (clone SP142, ZSGB-Bio, Beijing, China), followed by incubation with secondary antibody for 45 min at 37°C and immunoreactions were visualized using the ChemMate EnVision+ detection kit (Peroxidase/Dab, Rabbit/Mouse, K5007, Dako, Glostrup, Denmark).

Techniques: Expressing

Journal: Frontiers in Oncology

Article Title: Combined Association of Tumoral PD-L1 Expression and Pretreatment Presence of Epstein-Barr Virus DNA With Risk Stratification and Prognosis of Patients With Nasopharyngeal Carcinoma

doi: 10.3389/fonc.2021.791411

Figure Lengend Snippet: Representative immunohistochemistry of (A) negative, (B) weak, (C) moderate, and (D) strong PD-L1 staining in NPC tumor tissues. All the images are 40X magnification, The definition of negative was no staining, weak staining was yellow particles, moderate staining was yellow–brown, and strong staining was brown.

Article Snippet: The sections were stained overnight at 4°C with anti-PD-L1 primary antibody (clone SP142, ZSGB-Bio, Beijing, China), followed by incubation with secondary antibody for 45 min at 37°C and immunoreactions were visualized using the ChemMate EnVision+ detection kit (Peroxidase/Dab, Rabbit/Mouse, K5007, Dako, Glostrup, Denmark).

Techniques: Immunohistochemistry, Staining

Journal: Frontiers in Oncology

Article Title: Combined Association of Tumoral PD-L1 Expression and Pretreatment Presence of Epstein-Barr Virus DNA With Risk Stratification and Prognosis of Patients With Nasopharyngeal Carcinoma

doi: 10.3389/fonc.2021.791411

Figure Lengend Snippet: (A) Percentage of metastatic and non-metastatic NPC patients with high PD-L1 expression levels at diagnosis. (B) Percentage of metastatic and non-metastatic NPC patients who were EBV-positive at diagnosis.

Article Snippet: The sections were stained overnight at 4°C with anti-PD-L1 primary antibody (clone SP142, ZSGB-Bio, Beijing, China), followed by incubation with secondary antibody for 45 min at 37°C and immunoreactions were visualized using the ChemMate EnVision+ detection kit (Peroxidase/Dab, Rabbit/Mouse, K5007, Dako, Glostrup, Denmark).

Techniques: Expressing, Biomarker Discovery

Journal: Frontiers in Oncology

Article Title: Combined Association of Tumoral PD-L1 Expression and Pretreatment Presence of Epstein-Barr Virus DNA With Risk Stratification and Prognosis of Patients With Nasopharyngeal Carcinoma

doi: 10.3389/fonc.2021.791411

Figure Lengend Snippet: Evaluation of progression-free survival using the Kaplan-Meier survival analysis. (A) Patients with high PD-L1 expression is associated with shorter progression-free survival; (B) Patients with positive EBV status is associated with shorter progression-free survival; (C, D) Progression-free survival based on both PD-L1 expression levels and EBV status indicated that patients with high PD-L1 expression and positive EBV status is associated with shortest progression-free survival.

Article Snippet: The sections were stained overnight at 4°C with anti-PD-L1 primary antibody (clone SP142, ZSGB-Bio, Beijing, China), followed by incubation with secondary antibody for 45 min at 37°C and immunoreactions were visualized using the ChemMate EnVision+ detection kit (Peroxidase/Dab, Rabbit/Mouse, K5007, Dako, Glostrup, Denmark).

Techniques: Expressing

Journal: Frontiers in Oncology

Article Title: Combined Association of Tumoral PD-L1 Expression and Pretreatment Presence of Epstein-Barr Virus DNA With Risk Stratification and Prognosis of Patients With Nasopharyngeal Carcinoma

doi: 10.3389/fonc.2021.791411

Figure Lengend Snippet: Evaluation of overall survival using the Kaplan-Meier survival analysis. No overall survival difference is noted in NPC patients stratified according to PD-L1 expression, EBV status, and their combination. (A) Overall survival based on tumoral PD-L1 expression alone; (B) Overall survival based on EBV status alone; (C, D) Overall survival based on PD-L1 expression levels and EBV status.

Article Snippet: The sections were stained overnight at 4°C with anti-PD-L1 primary antibody (clone SP142, ZSGB-Bio, Beijing, China), followed by incubation with secondary antibody for 45 min at 37°C and immunoreactions were visualized using the ChemMate EnVision+ detection kit (Peroxidase/Dab, Rabbit/Mouse, K5007, Dako, Glostrup, Denmark).

Techniques: Expressing

Journal: Frontiers in Oncology

Article Title: Combined Association of Tumoral PD-L1 Expression and Pretreatment Presence of Epstein-Barr Virus DNA With Risk Stratification and Prognosis of Patients With Nasopharyngeal Carcinoma

doi: 10.3389/fonc.2021.791411

Figure Lengend Snippet: Univariate analysis of progression-free survival in patients with NPC.

Article Snippet: The sections were stained overnight at 4°C with anti-PD-L1 primary antibody (clone SP142, ZSGB-Bio, Beijing, China), followed by incubation with secondary antibody for 45 min at 37°C and immunoreactions were visualized using the ChemMate EnVision+ detection kit (Peroxidase/Dab, Rabbit/Mouse, K5007, Dako, Glostrup, Denmark).

Techniques: Expressing

Journal: Frontiers in Oncology

Article Title: Combined Association of Tumoral PD-L1 Expression and Pretreatment Presence of Epstein-Barr Virus DNA With Risk Stratification and Prognosis of Patients With Nasopharyngeal Carcinoma

doi: 10.3389/fonc.2021.791411

Figure Lengend Snippet: Multivariate analysis of progression-free survival in patients with NPC.

Article Snippet: The sections were stained overnight at 4°C with anti-PD-L1 primary antibody (clone SP142, ZSGB-Bio, Beijing, China), followed by incubation with secondary antibody for 45 min at 37°C and immunoreactions were visualized using the ChemMate EnVision+ detection kit (Peroxidase/Dab, Rabbit/Mouse, K5007, Dako, Glostrup, Denmark).

Techniques: Expressing

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Article Title: PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison

doi: 10.1158/1078-0432.CCR-16-1821

Figure Lengend Snippet: (A) Distribution of PD-L1 expression across antibodies for all melanoma specimens. (B) Representative plot showing percentage of total cells in 34 archival melanoma specimens demonstrating membranous PD-L1 staining with clones SP142 and 28-8. Each dot represents a single specimen. A strong correlation was observed, R2=0.938. (C) Pearson’s correlation coefficients for comparisons of percentage of total cells staining for PD-L1 between all studied clones.

Article Snippet: 21 Taken together with our results, these findings suggest that the Genentech SP142 assay likely differs in some other component —primary antibody concentration, antigen retrieval, amplification, or signal development — rather than the intrinsic ability of the antibody to label PD-L1 expression on tumor cells.

Techniques: Expressing, Staining, Clone Assay